Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

By CCF Clinical Trials | July 2, 2019

Study Name
	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
ClinicalTrials.gov Identifier (if applicable)
	NCT03602079
Clinical Trial Category (check all that apply)
	Beyond First Line Therapy Targeted Therapy
Study Center
Institution Name
	The University of Texas MD Anderson Cancer Center
City
	Houston
State
	Texas
Zip Code
	77030
Country
	United States
List additional Institutions (include address, phone number, and website)
	Florida Cancer Specialists & Research Institute Sarasota, Florida, United States, 34232 Beth Israel Deaconess Medical Center Cancer Center Boston, Massachusetts, United States, 02215 Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Clinical Research Alliance, Inc. Lake Success, New York, United States, 11042 Stephenson Cancer Center Oklahoma City, Oklahoma, United States, 73104 Providence Cancer Institute Portland, Oregon, United States, 97213 Mary Crowley Cancer Research Centers – Medical City Dallas, Texas, United States, 75230 South Texas Accelerated Research Therapeutics, LLC (START) San Antonio, Texas, United States, 78229 Virginia Cancer Specialist Fairfax, Virginia, United States, 22031
Study Contacts
Principal Investigator
	Jordi Rodon Ahnert, M.D., PhD
P.I. Phone
	(713) 563-1930
P.I. Email
	yjiang@mdanderson.org
List additional Principal Investigators (include phone number and email)
	Virginia Cancer Specialist Contact: Alexander Spira, MD, PhD,FACP 703-280-5390 Alexander.Spira@usoncology.com
Study Coordinator
	Yunfang (Jenny) Jiang
Study Coordinator Phone
	(713) 794-1751
Study Coordinator Email
	yjiang@mdanderson.org
List additional Study Coordinators (include phone number and email)
	Florida Cancer Specialists & Research Institute Contact: Donna L Jones, BSN, RN, OCN, 941-377-9993 Beth Israel Deaconess Medical Center Cancer Center Contact: Cassandra Cruz 617-975-7411 clcruz@bidmc.harvard.edu Karmanos Cancer Institute Contact: Valerie Davis 313-576-9370 davisv@karmanos.org Clinical Research Alliance, Inc. Contact: Colleen Kats ckats@researchcra.com Stephenson Cancer Center Contact: Dana Suters 405-271-8778 SCC-Clinical-Trials-Office@ouhsc.edu Providence Cancer Institute Contact: Christina Lopez 503-215-2614 Christina.Lopez4@providence.org Mary Crowley Cancer Research Centers – Medical City Contact: Amy Jordan 972-566-3000 referral@marycrowley.org South Texas Accelerated Research Therapeutics, LLC (START) Contact: Isabel Jimenez, RN, MSN 210-593-5265 isabel.jimenez@startsa.com
OVERVIEW – in layman’s terms (150 words max)
	Study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Cycles will continue until disease progression or unacceptable toxicity.
Enrollment
	102
Study Start Date
	07/16/2018
Estimated Completion Date
	01/10/2020